TRUCK (T-Cell Redirected for Universal Cytokine Killing) CAR-T Development Service

TRUCK CAR-T cells are engineered to not only target tumor cells but also locally release transgenic cytokines. This enables remodeling of the tumor microenvironment and enhances antitumor immune responses, thereby significantly improving their therapeutic potential against solid tumors. Creative Biolabs' TRUCK (T-Cell Redirected for Universal Cytokine Killing) CAR-T Development Service is committed to advancing the application of next-generation CAR-T technologies. Leveraging advanced gene editing platforms and extensive experience in cell therapy, we possess the capability to efficiently construct, optimize, and functionally validate TRUCK CAR-T cells.

Introduction

TRUCK CAR-T cells represent a fourth-generation chimeric antigen receptor T cell platform engineered to secrete transgenic cytokines, such as IL-12, upon antigen-specific activation within the tumor microenvironment. This innovative design not only enhances localized antitumor immunity by recruiting and activating innate immune cells but also mitigates systemic toxicity, thereby offering a promising strategy to overcome the immunosuppressive barriers and improve the efficacy of CAR-T therapy in solid tumors.

Fig.1 From scFv to TRUCK: The four-generation journey of CAR-T cell innovation.¹

TRUCK (T-Cell Redirected for Universal Cytokine Killing) CAR-T Development Service at Creative Biolabs

Creative Biolabs' TRUCK (T-Cell Redirected for Universal Cytokine Killing) CAR-T Development Service is engineered to overcome the immunosuppressive solid tumor microenvironment. Our platform integrates inducible cytokine payloads that remodel the TME upon antigen engagement, enhanced costimulatory domains for sustained T cell persistence, and advanced safety switches for precise control. Our approach effectively addresses the dual challenges of inadequate immune activation and therapeutic toxicity in solid tumor immunotherapy.

What We Can Offer

Our TRUCK CAR-T development service offers end-to-end solutions through sophisticated engineering platforms, strategic cytokine payloads designed to reshape the tumor microenvironment and enhance T cell fitness, and integrated safety mechanisms for precise control and risk mitigation.

Our Service Process

Required Starting Materials:

• Target Information: Detailed data on the chosen tumor-associated antigen (TAA), including expression profile and sequence.
• Source Cell Material: Autologous (patient leukapheresis material) or Allogeneic (donor or iPSC-derived) T cells.
• Target Criteria: Predefined specifications for transduction efficiency, target phenotype (e.g., Naïve/Memory ratio), and minimum cell count.

Key steps:

Final Deliverables:

• Final CAR-T Cell Product: Cryopreserved engineered T cells.
• Functional Assay Report: Detailed data confirming antigen-specific cytotoxicity, induced cytokine secretion kinetics, and persistence metrics in vitro.

Key Advantages

• Customized Construct Engineering: We offer full customization of your CAR construct, including selection of optimal scFv domains, integration of advanced costimulatory domains (e.g., 4-1BB, CD28, OX40), and tailored cytokine payload cassettes (IL-12, IL-18, or proprietary molecules).
• Advanced Gene Delivery System: Utilizing highly efficient viral vectors (Lentivirus or Retrovirus) manufactured at optimized conditions, guaranteeing high T cell transduction efficiency and stable, integrated gene expression.

FAQ

Why Choose Us?

Creative Biolabs specializes in advanced TRUCK CAR-T development, engineered to secrete inducible cytokine payloads such as IL-12 or IL-18 within the tumor microenvironment. Our platform enhances antitumor immunity while mitigating on-target/off-tumor risks. Trust us to deliver potent, scalable, and clinically safer cell therapies tailored for solid tumors.

Customer Reviews

"Using Creative Biolabs' TRUCK CAR-T Development Service in our research has significantly improved the functional persistence of our T cells in models mimicking the TME. The final result validated the required T-central memory phenotype, which is essential for durability." Dr. Kt Mr.

"Using Creative Biolabs' service facilitated our move from preclinical proof-of-concept to manufacturing validation without regulatory setbacks. Their closed-system approach for high-yield expansion directly led to a 35% cost reduction per dose compared to our previous manual process." Pl Ne.

How to Contact Us?

To initiate a project discussion or receive detailed technical specifications regarding our TRUCK CAR-T platform, please contact our expert team.

Reference

1. Andrea, Alain E et al. "Engineering Next-Generation CAR-T Cells for Better Toxicity Management." International journal of molecular sciences vol. 21, 228620. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms21228620.